{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T10:22:59Z","timestamp":1762078979153},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lipids Health Dis"],"published-print":{"date-parts":[[2007,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Patients with HIV are subject to development of HIV metabolic syndrome characterized by dyslipidemia, lipodystrophy and insulin resistance secondary to highly active antiretroviral therapy (HAART). Rosuvastatin is a highly potent HMG-CoA reductase inhibitor. Rosuvastatin is effective at lowering LDL and poses a low risk for drug-drug interaction as it does not share the same metabolic pathway as HAART drugs. This study sought to determine the efficacy of rosuvastatin on lipid parameters in HIV positive patients with HIV metabolic syndrome.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Mean TC decreased from 6.54 to 4.89 mmol\/L (25.0% reduction, p &lt; 0.001). Mean LDL-C decreased from 3.39 to 2.24 mmol\/L (30.8% reduction, p &lt; 0.001). Mean HDL rose from 1.04 to 1.06 mmol\/L (2.0% increase, p = ns). Mean triglycerides decreased from 5.26 to 3.68 mmol\/L (30.1% reduction, p &lt; 0.001). Secondary analysis examining the effectiveness of rosuvastatin monotherapy (n = 70) vs. rosuvastatin plus fenofibrate (n = 43) showed an improvement of 21.3% in TG and a decrease of 4.1% in HDL-C in the monotherapy group. The rosuvastatin plus fenofibrate showed a greater drop in triglycerides (45.3%, p &lt; 0.001) and an increase in HDL of 7.6% (p = 0.08).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>This study found that rosuvastatin is effective at improving potentially atherogenic lipid parameters in HIV-positive patients. The lipid changes we observed were of a smaller magnitude compared to non-HIV subjects. Our results are further supported by a small, pilot trial examining rosuvastatin effectiveness in HIV who reported similar median changes from baseline of -21.7% (TC), -22.4% (LDL-C), -30.1% (TG) with the exception of a 28.5% median increase in HDL. In light of the results revealed by this pilot study, clinicians may want to consider a possible resistance to statin therapy when treating patients with HIV metabolic syndrome.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1476-511x-6-27","type":"journal-article","created":{"date-parts":[[2007,10,25]],"date-time":"2007-10-25T04:39:43Z","timestamp":1193287183000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Are HIV positive patients resistant to statin therapy?"],"prefix":"10.1186","volume":"6","author":[{"given":"Kevin W.","family":"Johns","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew T.","family":"Bennett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory P.","family":"Bondy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2007,10,24]]},"reference":[{"key":"130_CR1","doi-asserted-by":"publisher","first-page":"F25","DOI":"10.1097\/00002030-200002180-00001","volume":"14","author":"A Carr","year":"2000","unstructured":"Carr A, Miller J, Law M, Cooper DA: A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. AIDS. 2000, 14: F25-32. 10.1097\/00002030-200002180-00001","journal-title":"AIDS"},{"key":"130_CR2","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1161\/01.CIR.100.7.700","volume":"100","author":"D Periard","year":"1999","unstructured":"Periard D, Telenti A, Sudre P, Cheseaux JJ, Halfon P, Reymond MJ, Marcovina SM, Glauser MP, Nicod P, Darioli R, Mooser V: Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. Circulation. 1999, 100: 700-5.","journal-title":"Circulation"},{"key":"130_CR3","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1097\/00002030-199909100-00009","volume":"13","author":"T Saint-Marc","year":"1999","unstructured":"Saint-Marc T, Partisani M, Poizot-Martin I, Bruno F, Rouviere O, Lang JM, Gastaut JA, Touraine JL: A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS. 1999, 13: 1659-67. 10.1097\/00002030-199909100-00009","journal-title":"AIDS"},{"key":"130_CR4","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1097\/00126334-200208150-00002","volume":"30","author":"D Klein","year":"2002","unstructured":"Klein D, Hurley LB, Quesenberry CP, Sidney S: Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection?. J Acquir Immune Defic Syndr. 2002, 30: 471-7.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"130_CR5","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/S0008-6363(02)00828-3","volume":"60","author":"G Barbaro","year":"2003","unstructured":"Barbaro G: HIV infection, highly active antiretroviral therapy and the cardiovascular system. Cardiovasc Res. 2003, 60: 87-95. 10.1016\/S0008-6363(02)00828-3","journal-title":"Cardiovasc Res"},{"key":"130_CR6","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1097\/00002030-200311210-00010","volume":"17","author":"M Mary-Krause","year":"2003","unstructured":"Mary-Krause M, Cotte L, Simon A, Partisani M, Costagliola D: Clinical Epidemiology Group from the French Hospital Database. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS. 2003, 17: 2479-86. 10.1097\/00002030-200311210-00010","journal-title":"AIDS"},{"key":"130_CR7","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1086\/378131","volume":"37","author":"MP Dube","year":"2003","unstructured":"Dube MP, Stein JH, Aberg JA, Fichtenbaum CJ, Gerber JG, Tashima KT, Henry WK, Currier JS, Sprecher D, Glesby MJ, : Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis. 2003, 37: 613-27. 10.1086\/378131","journal-title":"Clin Infect Dis"},{"key":"130_CR8","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1592\/phco.20.13.1066.35033","volume":"20","author":"SR Penzak","year":"2000","unstructured":"Penzak SR, Chuck SK, Stajich GV: Safety and efficacy of HMG-CoA reductase inhibitors for treatment of hyperlipidemia in patients with HIV infection. Pharmacotherapy. 2000, 20: 1066-71. 10.1592\/phco.20.13.1066.35033","journal-title":"Pharmacotherapy"},{"key":"130_CR9","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1016\/j.clinthera.2004.09.005","volume":"26","author":"JW Cheng","year":"2004","unstructured":"Cheng JW: Rosuvastatin in the management of hyperlipidemia. Clin Ther. 2004, 26: 1368-87. 10.1016\/j.clinthera.2004.09.005","journal-title":"Clin Ther"},{"key":"130_CR10","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1097\/01.aids.0000174458.86121.43","volume":"19","author":"L Calza","year":"2005","unstructured":"Calza L, Colangeli V, Manfredi R, Legnani G, Tampellini L, Pocaterra D, Chiodo F: Rosuvastatin for the treatment of hyperlipidaemia in HIV-infected patients receiving protease inhibitors: a pilot study. AIDS. 2005, 19: 1103-5.","journal-title":"AIDS"},{"key":"130_CR11","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1097\/00002030-200211080-00012","volume":"16","author":"J Miller","year":"2002","unstructured":"Miller J, Brown D, Amin J, Kent-Hughes J, Law M, Kaldor J, Cooper DA, Carr A: A randomised, double-blind study of gemfibrozil for the treatment of protease inhibitor-associated hypertriglyceridaemia. AIDS. 2002, 16: 2195-200. 10.1097\/00002030-200211080-00012","journal-title":"AIDS"},{"key":"130_CR12","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1097\/QAD.0b013e32801120e3","volume":"20","author":"F Boccara","year":"2006","unstructured":"Boccara F, Simon T, Lacombe K, Cohen A, Laloux B, Bozec E, Durant S, Girard PM, Laurent S, Boutouyrie P: Influence of pravastatin on carotid artery structure and function in dyslipidemic HIV-infected patients receiving antiretroviral therapy. AIDS. 2006, 20: 2395-8. 10.1097\/QAD.0b013e32801120e3","journal-title":"AIDS"},{"key":"130_CR13","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1111\/j.1463-1326.2004.00450.x","volume":"7","author":"S Stender","year":"2005","unstructured":"Stender S, Schuster H, Barter P, Watkins C, Kallend D, : Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial. Diabetes Obes Metab. 2005, 7: 430-8. 10.1111\/j.1463-1326.2004.00450.x","journal-title":"Diabetes Obes Metab"},{"key":"130_CR14","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1067\/mhj.2002.129312","volume":"144","author":"WV Brown","year":"2002","unstructured":"Brown WV, Bays HE, Hassman DR, McKenney J, Chitra R, Hutchinson H, Miller E, : Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: a randomised, double-blind, 52-week trial. Am Heart J. 2002, 144: 1036-43. 10.1067\/mhj.2002.129312","journal-title":"Am Heart J"},{"key":"130_CR15","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1097\/00149831-200502000-00004","volume":"12","author":"M Hirsch","year":"2005","unstructured":"Hirsch M, O'Donnell JC, Jones P: Rosuvastatin is cost-effective in treating patients to low-density lipoprotein-cholesterol goals compared with atorvastatin, pravastatin and simvastatin: analysis of the STELLAR trial. Eur J Cardiovasc Prev Rehabil. 2005, 12: 18-28. 10.1097\/00149831-200502000-00004","journal-title":"Eur J Cardiovasc Prev Rehabil"},{"key":"130_CR16","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1067\/mhj.2002.128049","volume":"144","author":"AG Olsson","year":"2002","unstructured":"Olsson AG, Istad H, Luurila O, Ose L, Stender S, Tuomilehto J, Wiklund O, Southworth H, Pears J, Wilpshaar JW, : Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia. Am Heart J. 2002, 144: 1044-51. 10.1067\/mhj.2002.128049","journal-title":"Am Heart J"},{"key":"130_CR17","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/S0002-9149(01)01727-1","volume":"88","author":"AG Olsson","year":"2001","unstructured":"Olsson AG, Pears J, McKellar J, Mizan J, Raza A: Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia. Am J Cardiol. 2001, 88: 504-8. 10.1016\/S0002-9149(01)01727-1","journal-title":"Am J Cardiol"},{"key":"130_CR18","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1185\/030079903125002405","volume":"19","author":"JM McKenney","year":"2003","unstructured":"McKenney JM, Jones PH, Adamczyk MA, Cain VA, Bryzinski BS, Blasetto JW, : Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial. Curr Med Res Opin. 2003, 19: 689-98. 10.1185\/030079903125002405","journal-title":"Curr Med Res Opin"},{"key":"130_CR19","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/S0002-9149(01)02226-3","volume":"89","author":"M Davidson","year":"2002","unstructured":"Davidson M, Ma P, Stein EA, Gotto AM, Raza A, Chitra R, Hutchinson H: Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia. Am J Cardiol. 2002, 89: 268-75. 10.1016\/S0002-9149(01)02226-3","journal-title":"Am J Cardiol"},{"key":"130_CR20","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/S0002-9149(02)02994-6","volume":"91","author":"DW Schneck","year":"2003","unstructured":"Schneck DW, Knopp RH, Ballantyne CM, McPherson R, Chitra RR, Simonson SG: Comparative effects of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease. Am J Cardiol. 2003, 91: 33-41. 10.1016\/S0002-9149(02)02994-6","journal-title":"Am J Cardiol"},{"key":"130_CR21","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1136\/hrt.2004.056523","volume":"92","author":"D Hurlimann","year":"2006","unstructured":"Hurlimann D, Chenevard R, Ruschitzka F, Flepp M, Enseleit F, Bechir M, Kobza R, Muntwyler J, Ledergerber B, Luscher TF, Noll G, Weber R: Effects of statins on endothelial function and lipid profile in HIV infected persons receiving protease inhibitor-containing anti-retroviral combination therapy: a randomised double blind crossover trial. Heart. 2006, 92: 110-2. 10.1136\/hrt.2004.056523","journal-title":"Heart"},{"key":"130_CR22","first-page":"E18","volume":"147","author":"JH Stein","year":"2004","unstructured":"Stein JH, Merwood MA, Bellehumeur JL, Aeschlimann SE, Korcarz CE, Underbakke GL, Mays ME, Sosman JM: Effects of pravastatin on lipoproteins and endothelial function in patients receiving human immunodeficiency virus protease inhibitors. Am Heart J. 2004, 147: E18-","journal-title":"Am Heart J"},{"key":"130_CR23","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/S0735-1097(01)01783-1","volume":"39","author":"Y Sawayama","year":"2002","unstructured":"Sawayama Y, Shimizu C, Maeda N, Tatsukawa M, Kinukawa N, Koyanagi S, Kashiwagi S, Hayashi J: Effects of probucol and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia. Fukuoka Atherosclerosis Trial (FAST). J Am Coll Cardiol. 2002, 39: 610-6. 10.1016\/S0735-1097(01)01783-1","journal-title":"J Am Coll Cardiol"},{"key":"130_CR24","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/1476-511X-6-15","volume":"6","author":"MT Bennett","year":"2007","unstructured":"Bennett MT, Johns KJ, Bondy GP: Ezetimibe is effective when added to maximally tolerated lipid lowering therapy in patients with HIV. Lipids Health Dis. 2007, 6: 15- 10.1186\/1476-511X-6-15","journal-title":"Lipids Health Dis"}],"container-title":["Lipids in Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1476-511X-6-27.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T23:01:48Z","timestamp":1630450908000},"score":1,"resource":{"primary":{"URL":"https:\/\/lipidworld.biomedcentral.com\/articles\/10.1186\/1476-511X-6-27"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,10,24]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,12]]}},"alternative-id":["130"],"URL":"https:\/\/doi.org\/10.1186\/1476-511x-6-27","relation":{},"ISSN":["1476-511X"],"issn-type":[{"value":"1476-511X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,10,24]]},"assertion":[{"value":"13 August 2007","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2007","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2007","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"27"}}